Latest Litigation News

Triangle Energy (ASX:TEG) has regained 100% ownership of the L7 Production Licence and EP 437 Exploration Permit in the Perth Basin after joint venture partners Echelon and Strike withdrew and transferred their interests back. Legal proceedings against these partners for failing farm-in obligations continue.

Dateline Resources has pinpointed three priority zones for heavy rare earth exploration at its Music Valley project in California, following a detailed helicopter-borne geophysical survey that revealed structurally complex areas with elevated thorium signatures.

Strata Investment Holdings has dismissed a cash acquisition proposal from Freedom BidCo, citing undervaluation, even as it raises A$8 million to fund strategic investments and litigation.

The High Court of New Zealand has dismissed Talley’s application to pursue a derivative claim on behalf of Bathurst Resources, maintaining confidentiality around ongoing litigation.

Bounty Oil & Gas NL has issued a prospectus offering over 632 million new options to eligible investors as part of a broader recapitalisation, potentially raising $6.3 million if exercised.

Mayne Pharma has received $14.4 million from Cosette Pharmaceuticals covering legal costs and interest following a Supreme Court ruling in its favour. The legal battle continues with Cosette’s appeal decision pending.

ANZ Bank New Zealand has lodged an appeal against a High Court summary judgment in a class action related to consumer credit laws, prolonging legal uncertainty for the lender.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Classic Minerals has taken a decisive step towards mining at its Forrestania project by issuing a formal Notice of Decision to Commence Mining for the Lady Ada and Lady Magdalene deposits, despite ongoing legal challenges.

Phoslock Environmental Technologies reported a sales recovery in 2025 with further growth expected, backed by resumed production in China and promising European projects, while ongoing litigation clouds the outlook.

EROAD reported flat group revenue of NZD 195.2 million for FY26, driven by strong Australian growth and steady New Zealand performance, offset by a North American decline and a hefty goodwill impairment.

Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales after successfully defending against Cosette Pharmaceuticals’ claims tied to a terminated acquisition deal.